Screener
Veradermics MANE Shares (Diluted)
Shares (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Veradermics in its filing.
Tagged under the XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding.
The source filing: Veradermics’s 10-Q, filed May 12, 2026.
- Filed
- May 12, 2026, 5:06 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001827635-26-000019
| (in thousands, except share and per share amounts) | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Net loss | $(27,232) | $(12,400) |
| Net loss attributable to common stock | $(30,011) | $(14,582) |
| Net loss per share of common stock, basic and diluted | $(1.32) | $(19.79) |
| Weighted average common stock outstanding, basic and diluted | 22,704,124 | 736,933 |
| Other comprehensive loss: | ||
| Net unrealized losses on marketable securities | (584) | — |
| Total other comprehensive loss | (584) | — |
| Total comprehensive loss | $(27,816) | $(12,400) |
Item 1. Condensed Consolidated Financial Statements (
FAQ
- What is Veradermics's shares (diluted)?
- Veradermics (MANE) reported shares (diluted) of 22.7M in Q1 2026.
- What does shares (diluted) mean?
- The weighted-average shares outstanding plus all potentially dilutive shares from stock options, RSUs, convertible securities, and warrants, using the treasury stock method.
Ask your AI about Veradermics's shares (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude